Linvoseltamab for Patients with Relapsed/Refractory Multiple Myeloma
The group describes the clinical gaps that prompted development of bispecifics and summarizes the currently available agents for relapsed/refractory disease.
Key Background Information on Bispecific Antibodies
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Defining Relapse and Switching Therapies in Multiple Myeloma
First-line Therapy Options in Multiple Myeloma
Epidemiology and Prognosis of Multiple Myeloma
Introduction and Pathophysiology of Multiple Myeloma
